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The role of reactive oxygen
species in the immunity induced
by nano‑pulse stimulation
Siqi Guo*, Niculina I. Burcus, Megan Scott, Yu Jing & Iurii Semenov
Reactive oxygen species (ROS) are byproducts of tumor cells treated with Nano-Pulse Stimulation
(NPS). Recently, ROS have been suggested as a contributing factor in immunogenic cell death and T
cell-mediated immunity. This research further investigated the role of NPS induced ROS in antitumor
immunity. ROS production in 4T1-luc breast cancer cells was characterized using three detection
reagents, namely, Amplex Red, MitoSox Red, and Dihydroethidium. The efficiency of ROS quenching
was evaluated in the presence or absence of ROS scavengers and/or antioxidants. The immunogenicity
of NPS treated tumor cells was assessed by ex vivo dendritic cell activation, in vivo vaccination
assay and in situ vaccination with NPS tumor ablation. We found that NPS treatment enhanced the
immunogenicity of 4T1-luc mouse mammary tumor, resulted in a potent in situ vaccination protection
and induced long-term T cell immunity. ROS production derived from NPS treated breast cancer cells
was an electric pulse dose-dependent phenomenon. Noticeably, the dynamic pattern of hydrogen
peroxide production was different from that of superoxide production. Interestingly, regardless
of NPS treatment, different ROS scavengers could either block or promote ROS production and
stimulate or inhibit tumor cell growth. The activation of dendritic cells was not influenced by blocking
ROS generation. The results from in vivo vaccination with NPS treated cancer cells suggests that ROS
generation was not a prerequisite for immune protection.
Nano-Pulse Stimulation (NPS) is an approach where cells are treated by nanosecond range electric pulses with
short rise and fall times and high electric field strength (10–68 kV/cm), also referred to as nanosecond pulsed
electric fields or nanosecond electric pulses1,2 in other biological processes. NPS has been demonstrated to be an
effective tumor ablation method for various types of cancer in animal models, such as mouse m
 elanoma3,4 breast
5
6
7
cancer , pancreatic cancer , xenograft human breast cancer , xenograft human pancreatic cancer3, and mouse
and rat hepatocellular carcinoma8. A small clinical trial shows NPS treatment alone is sufficient to completely
ablate basal cell carcinoma9. In addition to local tumor ablation, a vaccine-like effect has also been reported by
several groups8,10 including ours5. While the exact mechanisms behind a vaccine-like immunogenic cell death
[ICD] induced by NPS have not been clearly depicted, they are being s tudied5,10,11.
NPS was suggested as a novel type of ICD i nducer11. Immune response and vaccine-like protection elicited
by NPS treatment has been observed in multiple cancer models, such as rat hepatocellular carcinoma8, mouse
melanoma10,12, mammary cancer5, lymphoma, colorectal carcinoma13 and pancreatic cancer6,14. We previously
demonstrated that NPS treated 4T1 cells exhibited Calreticulin [CRT] exposure on the cell surface, released
both ATP and HMGB15, and activated dendritic cells in vitro, as evidenced by significant upregulation of costimulatory molecules CD40, CD86, and MHC-II. These hallmarks of I CD15–19 were reported in other cancer cells
treated with NPS by Nuccitelli’s11 and Muratori’s13 groups as well. Taken together, substantial evidence supports
NPS is an authentic ICD inducer. However, its underlying mechanisms are not fully clarified.
ICD is a common name for cell death that leads to immune r esponses18,20,21. Reactive oxygen species [ROS]
have been demonstrated to play an essential role in the ICD induced by Hypericin based photodynamic therapy
as a type II ICD inducer22,23. ROS generation and the associated endoplasmic reticulum stress occur in the
process of cell death induced by many type I ICD inducers as w
 ell24. Since ROS generation is mainly a collateral
effect of these ICD inducers, the importance of ROS itself as a type I ICD inducer is not clear. ROS signaling
pathways have been proven necessary for cell survival, play important roles in cancer development and cell
death signaling25,26, and are also capable of inducing various types of death pathways27. ROS were reported to
trigger ICD and consequently result in antitumor immune response28. On the contrary, ROS were demonstrated
to mediate immune suppression as w
 ell29,30. Interestingly, ROS release has been reported by two groups in cells
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Figure 1.  NPS treatment induces antitumor immunity and long-term memory T cell responses. (A) 4T1-luc
tumor growth curves in mice immunized with 2 × 106 4T1-luc cells treated with 3-cycles of freeze/thaw, or
NPS (60 ns, 50 kV/cm, 1 Hz and 120 pulses). The number of tumor free (red) vs total mice are indicated. (B)
Survival curves of animals after the secondary tumor challenge. Mice with orthotopic 4T1-luc breast tumors
(6–8 mm) were treated with NPS (100 ns, 50 kV/cm, 3 Hz and 1000 pulses). Animals with tumor free over
7 weeks were challenged orthotopically in a different mammary fat pad with 0.5 × 106 live 4T1-luc tumor cells.
Ctrl: naïve mice without prior NPS treatment (n = 14). NPS: tumor free mice after NPS treatment (n = 14). (C)
The frequency of tissue resident memory CD8+ T (Trm) cells in draining lymph nodes. Tumor: control animals
without NPS treatment (n = 5). NPS: 9 days after NPS treatment (n = 5). (D) The frequencies of effector (Tem)
and central (Tcm) memory T cells in spleen. (E) Representative flow plots of intracellular cytokine staining for
IFN-γ and IL-17 in T cells from splenocytes cocultured with anti-CD3 for 6 h. For both (D, E), Tumor: control
animals without NPS were euthanized at day 35 after tumor initiation (n = 3). NPS: animals with tumor free
over 3 months after NPS treatment were euthanized (n = 5). *p < 0.05. **p < 0.01. ***p < 0.001. (Chi-Square for A,
LogRank for B and t test for C, D, respectively).
treated with N
 PS31,32. Currently, there has been no reported research defining the role of ROS in NPS induced
immunity. The determination of immunomodulation effects of ROS in NPS cancer treatment may provide an
enhancement approach for the NPS-induced antitumor immunity. In this study we assessed effects of ROS on 4T1
breast cancer cells treated with NPS and determined their role in the immunity resulting from NPS treatment.

Results

NPS treatment enhances tumor immunogenicity, results in potent in situ vaccination protec‑
tion and elicits T cell memory. Previously, we reported that 4T1-luc cells treated with NPS released sur-

rogate biomarkers of ICD including calreticulin, ATP and high mobility group protein B, and activated DCs
in vitro5. To further validate if NPS treatment can enhance the immunogenicity of 4T1-luc breast cancer, in vivo
vaccination assays were carried out. As shown in Fig. 1A, 4T1-luc cells are poorly immunogenic. All mice immunized with tumor lysate prepared by 3 cycles of freeze/thaw grew tumors, hence resulted in no protection (0%
or 0/12) against live tumor challenge. On the contrary, half of mice (50% or 6/12) immunized with NPS-treated
4T1-luc cells rejected live tumor challenge. Therefore, our in vivo vaccination assays indicate NPS is a bona fide
ICD inducer.
To assess if NPS treatment in vivo can improve the immunogenicity of cancer, hence turn the tumor itself
into vaccine (in situ vaccination), we first treated 4T1-luc tumors with NPS then animals with complete tumor
regression seven weeks after NPS treatment were challenged again with the same type of live cancer cells, but
at a different location. A potent rejection of tumor growth was shown in Fig. 1B. In contrast to that none of the
(0% or 0/14) naïve mice were protected, 93% (13/14) of mice having been treated with NPS were protected from
the secondary tumor challenge. This phenomenon of in situ vaccination protection has also been demonstrated
 odel8 and a mouse pancreatic cancer m
in a rat hepatocellular cancer m
 odel14 treated with NPS.
The mechanisms of NPS-induced potent in situ vaccination protection are unknown. We hypothesize that T
cell immunity plays a critical role in the in situ vaccination protection. To test our hypothesis, we examined both
early and long-term immune responses. Tissue-resident memory CD8 T cells were significantly increased in
draining lymph nodes 9 days after NPS treatment (Fig. 1C). In long-term, central memory and effector memory
CD4/8 T cells were remarkedly expanded 9–25 folds in tumor-free mice after NPS treatment in comparison to
tumor-bearing animals (Fig. 1D). Furthermore, intracellular cytokine staining showed a prominent population
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Figure 2.  ROS production in 4T1-luc cells treated with NPS. 4T1-luc breast cancer cells were treated with
NPS (60 ns, 50 kV/cm, 1 Hz with various pulses numbers). (A) and (B) ROS (H2O2) was measured by the
Amplex Red Kit. (C) ROS (Intracellular superoxide) was detected by dihydroethidium (DHE). Ctrl: control cells
without NPS treatment. 10p or 20p, 40p and 100p: treated with NPS with 10 or 20, 40 and 100 pulses (n = 8 each
treatment). RFU: relative fluorescence unit. Error bars represent standard errors (n = 8). *p < 0.05, **p < 0.01 and
***p < 0.001 by One Way ANOVA. The double lines indicate one groups vs the other two groups with nearly
identical results, respectively.

of IFN-γ producing CD4 and CD8 T cells in the spleen of NPS treated mice (Fig. 1E). These analyses suggest T
cell immunity is involved in the NPS-induced in situ vaccination protection.
However, major molecular events occurring in tumor cells after NPS treatment that are responsible for DC
activation and T cell priming are unexplored. To investigate whether ROS are involved in this process, next we
evaluate ROS production from tumor cells and defined their role in the NPS induced ICD.

ROS production derived from NPS treated 4T1‑luc cells is a dose‑dependent phenome‑
non. Determining the kinetics of ROS generation by cells remains a challenge because of their highly active

nature and inclusion of multiple species of chemically reactive molecules. Hydrogen peroxide H2O2 is most
commonly measured because it is relatively stable and has a longer half-life amongst other ROS molecules33. As
 2O2 levels correlate with the number of nanosecond electric pulses applied. Within 24 h
shown in Fig. 2A,B, H
after treatment, H2O2 levels also show time dependent increases. The concentration of H2O2, 1–4 μM in 1–4 h
after exposure to 100 pulses, that our group obtained, is higher than that reported by Dr. Pakhomov’s group31.
Considering that even 100 μM H2O2 does not have toxicity to 4T1 cells34, this level of H2O2 induced by NPS is
unlikely to impact cell viability however, importantly, it can serve as an intracellular signaling molecule.
Besides measuring H2O2, DHE has been often used to measure intracellular superoxide levels35–37. The superoxide level increased in an NPS dose-dependent manner within as early as 5 min after NPS treatment. As shown
in Fig. 2C, cells treated with the lethal dose (100 pulses) of NPS produced the highest level of superoxide. Regardless of pulse numbers applied, levels of superoxide peaked in 45 min and remained relatively stable for up to at
least 3 h. This pattern of superoxide release is very different from that of H2O2, showing continuous increases of
H
 2O2 levels in the first 4 h upon pulse delivery (Fig. 2B).
MitoSox red reagent has been utilized for selective detection of superoxide changes in the mitochondria38. A
significant increase of red fluorescence level has been observed in cells treated with 100 pulses after overnight
incubation at 37 °C (Fig. 3A–F). In contrast, control cells showed a low level of superoxide. Noticeably, there
is also a large difference between control cells and NPS treated cells in terms of cell morphology. Control cells
attach well, with sheets of cells and even the size of the nucleus, whereas a high heterogeneity of NPS treated
cells in size, shape, and nuclear morphology suggests that they are undergoing the dying process and are at different stages of this process.

ROS scavengers can block or promote ROS production induced by NPS depending on the
concentration and type.. There are many ROS scavengers and antioxidants available to quench or block

ROS production. We screened several commercially available ROS scavengers to determine which are the best
at reducing or blocking ROS production with minimal impact on cell viability. Trolox was reported to effectively block ROS production induced by NPS treatment in human pancreatic cancer cells BxPC-332. Our results
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Figure 3.  Intracellular ROS increase after NPS treatment. 4T1-luc breast cancer cells were treated with NPS and
incubated at 37 °C overnight. After stained with 5 μM MitoSOX red and 0.5 μg/mL Hoechst 33,342 cells were
examined under fluorescence microscope. (A) and (D) images show oxidized MitoSOX red; (B, C) and (E, F)
images show both nuclear stained with Hoechst 33,342 (blue) and cytoplasm stained with oxidized MitoSOX
red (red). Control: cells without NPS treatment. NPS: cells treated with NPS, 60 ns, 50 kV/cm, 1 Hz and 100
pulses. One representative image from three samples with the same treatment was presented.
showed that in 4T1-luc cells Trolox (1 mM) completely blocked H2O2 production induced by NPS but had no
effect on spontaneous H2O2 generation (Fig. 4A). However, RA, which has been reported to have ROS scavenger a ctivity39, only slightly reduced the H2O2 production induced by NPS. Pre-incubation with RA (100 μM)
decreased the concentration of H2O2 in 4T1-luc cells (measured 1 h after NPS exposure) by only 18.5%. No
significant changes occurred with RA applied at a lower concentration (10 μM) (Fig. 4B). Other ROS scavengers,
Vitamin C40, NAC41, and sodium pyruvate42 have been reported to reduce ROS production and to protect cells
from the ROS-related toxicity. Surprisingly, both Vitamin C (0.5 mM) and NAC (3 mM) significantly elevated
H
 2O2 production induced by NPS treatment. Overall, cells pre-incubated with Vitamin C produced much more
H2O2 than control cells (Fig. 4C). In contrast, cells pre-incubated with NAC showed the same level of H
 2O2 as
control cells at the start but gradually generated more H2O2 over time (Fig. 4C). Sodium pyruvate (10 mM) was
able to reduce H2O2 production induced by NPS treatment close to control levels and did not enhance spontaneous H2O2 generation.

ROS scavengers can impact cell viability at low NPS doses but have lesser effects at lethal
NPS doses.. Next, we studied if ROS scavengers could impact cancer cell viability following NPS treatment.

As shown in Fig. 4, most antioxidants do not affect 4T1-luc cell growth (Fig. 5A). On the other hand, sodium
pyruvate (SP), at 10 mM, stimulated growth of 4T1-luc cells whereas NAC at 3 mM showed toxicity to 4T1-luc
cells (Fig. 5B). The viability of 4T1-luc cells increased by 23% with the addition of 10 mM sodium pyruvate and
decreased 51% with the addition of 3 mM NAC (Fig. 5B). In 4T1-luc cells antioxidants showed various levels of
protection at low doses of NPS but were less potent or lost their effectiveness at high doses of NPS. For instance,
viability of 4T1-luc cells treated with 40 pulses increased by 80%, 27%, 65%, 146% and 44% with the addition of
RA 0.1 mM, Trolox 1 mM, Vitamin C 0.5 mM (Fig. 5A), sodium pyruvate 10 mM, and NAC 3 mM, respectively
(Fig. 5B). Nevertheless, when 4T1-luc cells were treated with 100 or 150 pulses which resulted in 95–100% of cell
death, only Trolox and sodium pyruvate exhibited some extent of protection. This falls in-line with their potency
of blockage of ROS production generated by high dose of NPS (Fig. 4A,C).

ROS scavengers do not block ex vivo dendritic cell activation by NPS‑treated 4T1‑luc
cells. Activation or maturation of dendritic cells is a prerequisite of immune response induction. Here we

examined five cell surface molecules commonly used as biomarkers for dendritic cell activation. Consistent with
our previous report, incubation of dendritic cells with NPS treated 4T1-luc cells upregulates MHC-I, CD40,
CD80 and CD86 markers (Fig. 6A,B). However, 1 mM Trolox, which was shown to effectively block H2O2 generation in 4T1 cells treated with NPS (Fig. 3A), did not change the expression of these activation markers except
the partial inhibition of CD80 upregulation by NPS. In contrast, dendritic cells stimulated with LPS expressed
the highest level of MHC-I, MHC-II, CD40, and CD86.

Blockade of ROS production does not diminish immunogenicity of NPS treated 4T1‑luc
cells. To examine if immune protection induced by NPS is affected by ROS blockers, in vivo vaccination
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Figure 4.  Effect of ROS scavengers/antioxidants on the ROS production induced by NPS. 4T1-luc cells were
pretreated with various potential ROS blockers then pulsed with NPS (60 ns, 50 kV/cm, 1 Hz and 100 pulses).
The kinetics of ROS (H2O2) was examined by Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit. (A). Effect
of Trolox on the H
 2O2 generation. (B) Effect of Rosmarinic acid (RA) on the on the H
 2O2 generation. (C) Effect
of N-acetyl cysteine (NAC), Vitamin C or SP on the H2O2 generation. 4T1: 4T1-luc cells without NPS treatment
as control. NPS: treated with NPS alone. Trolox, RA, NAC, Vit C or SP: pretreated with Trolox (1 mM), RA
(100 μM or 10 μM), NAC (3 mM), Vitamin C (0.5 mM) or sodium pyruvate (10 mM). Error bars represent
standard errors (n = 8). *p < 0.05 and ***p < 0.001 by One Way ANOVA. The double lines indicate one group vs
the other two groups with nearly identical results, respectively.
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Figure 5.  Effect of ROS blockers on the viability of cells treated with NPS. 4T1-luc cells were preincubated
with various ROS blockers for 30 min at 37 °C then 100 μL, cells at a concentration of 5 × 106 cells/mL in a
0.1 cm-gap cuvette were treated with NPS (60 ns, 50 kV/cm, 1 Hz and pulse numbers indicated). Cell viability
was measured by WST assays after an 18-h incubation at 37 °C and 5% CO2. (A) Effect of rosmarinic acid (RA),
Trolox and Vitamin C on the cell viability. Control: cells treated with NPS alone; RA (0.1 mM), Trolox (1 mM)
or Vit C (0.5 mM): preincubated with RA at 0.1 mM, Trolox at 1 mM or Vitamin C at 0.5 mM then treated with
NPS. (B) Effect of SP and NAC on the cell viability. Control: cells treated with NPS alone; SP (10 mM) or NAC
(3 mM): cells preincubated with sodium pyruvate at 10 mM or N-acetyl cysteine at 3 mM then treated with
NPS. Error bars represent standard deviations (n = 8). *p < 0.05, **p < 0.01 and ***p < 0.001 by One Way ANOVA.
assays were carried out. Since our in vitro results showed Trolox and sodium pyruvate were effective ROS blockers for the abolition or reduction of H
 2O2 induced by a lethal dose of NPS, the next step was to test if the blockade or reduction of ROS could eliminate or diminish the immune protection of NPS treated 4T1-luc cells. As
shown in Fig. 7A, immunization with NPS treated cells protected 60% (3/5) of animals from live tumor challenge
whereas tumor lysed by freeze/thaw as the antigen source did not result in any animal protection (0/5). Both
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Figure 6.  Effect of Trolox on cell surface markers of dendritic cells stimulated with NPS treated breast
cancer cells. Bone marrow derived dendritic cells (BMDCs) were incubated with media only (Control),
lipopolysaccharide (LPS) 5 μg/mL, the NPS-treated 4T1 cells (NPS) or the NPS treated 4T1-luc cells with Trolox
1 mM (NPS + Trolox). Two day later, cells were collected for the analysis of surface activation markers by flow
cytometry. (A) Results of one representative histogram for each treatment from two independent experiments
(n = 3 and 4, respectively) were shown here. (B) Expression of cell surface molecules of dendritic cells was
measured by mean fluorescent intensity (MFI). Error bars represent standard deviations (n = 4). *p < 0.05,
**p < 0.01 and ***p < 0.001 by One Way ANOVA.
the reduction and abolition of ROS did not decrease protection rates, which were 80% or 100%, respectively, to
NPS treated cells with the addition Trolox or sodium pyruvate. The rate of protection by NPS with the addition
of Trolox or SP was actually higher than that of NPS alone treated 4T1-luc cells. Although such a rate increase
did not reach statistical significance, the results suggest ROS production or H2O2 levels do not play a role in the
immunity induced by NPS for the 4T1-luc breast cancer model. One issue with this vaccination approach was
that tumor could grow at the vaccination site. As shown in Fig. 7B, no mice immunized with frozen/thawed cells
grew tumor at the vaccination site, however, some of the mice immunized with NPS treated cells did grow tumor
at the vaccination site. There were 40% (2/5), 20% (1/5), or 60% (3/5) of mice growing tumor after vaccination
with 4T1-luc cells treated with NPS, with additional Trolox, or with sodium pyruvate, respectively. Based on
our viability assays, the dose of adopted NPS (100 pulses 60 ns, 50 kV/cm at 1 Hz) could kill 95–99% of 4T1-luc
cells. However, this result indicated that only 30,000–150,000 (1–5% out of 3 × 106) surviving 4T1-luc cells were
sufficient to establish a tumor. Viability assays could also explain why more tumors grew at the vaccination site
in animals immunized with NPS and sodium pyruvate treated cells. Mainly because sodium pyruvate increased
the viability of cells treated with a lethal dose of NPS (Fig. 5B).

Discussion

We validated NPS is an authentic ICD inducer and induced a potent in situ vaccination protection in a poorly
immunogenic mouse breast cancer model. Significant increase of memory T cells were associated with longterm immune protection against live tumor challenge. We observed dose-dependent ROS production in 4T1-luc
breast cancer cells treated with NPS. We found that certain ROS scavengers/antioxidants did block or reduce
ROS production while other scavengers/antioxidants did not reduce but, in fact, even promoted ROS production following NPS treatment. ROS scavengers Trolox and RA showed protective effects when cells were treated
with low doses of NPS but were less effective in cells treated with lethal doses of NPS. Nevertheless, we were
able to identify two ROS scavengers that could effectively block ROS production after NPS treatment in 4T1-luc
breast cancer cells. Importantly, the blockade of ROS by these two ROS scavengers neither altered the activation
of dendritic cells nor reduced the vaccine effect of NPS treated cells. Therefore, ROS production is unlikely the
decisive factor of NPS induced vaccine effects.
Our data together with our p
 ublication5 suggest NPS is an ICD inducer for breast cancer. Rossi et al. reported
that NPS can enhance the immunogenicity of mouse MCA205 fibrosarcoma and CT-26 colon cancer. Vaccination
with NPS treated EL-4 lymphoma and CT-26 cancer cells also protected 50% and 78% of animals against live
tumor challenge, respectively13. Importantly, NPS tumor ablation elicits a strong in situ vaccination protection
Scientific Reports |
Vol:.(1234567890)

(2021) 11:23745 |

https://doi.org/10.1038/s41598-021-03342-4

nature portfolio

6

www.nature.com/scientificreports/

A

1: 1soo
,S 1500
~
::::,

0

600

t=

0

300
0

20

40

60

0

20

40

60

0

20

40

60

0

Days

Days

20

40

60

Days

B

600

E
E 500
C1I

(5/5 * )

(4/5 * )

Days
..,

NPS+SP

NPS+Trolo

(3/5)

(0/5)

1200
900

...>0

E

NPS

Frozen/thawed

Frozen/thawed

(0/5)

NPS

NPS+Trolox

NPS+SP

(2/5)

(1/5)

(3/5)

400

E
::::, 300
0

...>0

200
100

t=

0

E

0

20

40

Days

60

0

20

40

60

0

Days

20

40

Days

60

0

20

40

60

Days

Figure 7.  Effect of ROS blockers on the NPS induced immune protection. Female Balb/c mice were immunized
subcutaneously with 4T1-luc tumor lysate (Frozen/Thawed), NPS treated cells (NPS), NPS treated cells
with preincubation of Trolox 1 mM (NPS + Trolox) or sodium pyruvate 10 mM (NPS + SP). Ten days after
immunization animals (n = 5 for each group) were challenged with intra-mammary live 4T1-luc cells. (A)
Growth curves of challenge intra-mammary tumors. Numbers indicate animals with challenge tumor rejection
above total animals. (B) Growth curves of subcutaneous tumors at the immunization sites. Due to large
variations in tumor volumes, tumor growth curves in each group are shown as individual mice. Each curve
represents tumor growth in one mouse. The rates of vaccine protection (tumor rejection) or tumor growth are
compared among treatment groups. Numbers indicate animals with subcutaneous tumor growth above total
animals. *p < 0.05 by Chi square test.
as well. Various rates of in situ vaccination protection were observed in other cancer models treated with NPS.
NPS treatment can result in 100% (21/21), 75% (8/12) or 33% (6/18) of animals rejecting the secondary live
tumor challenge, respectively, in rat N1S1 hepatocellular8, mouse Pan02 pancreatic14 or B16 melanoma12 models.
Diverse immune outcomes following NPS treatment in different cancer models emphasize the importance
of its underlying mechanisms. Previously, we discovered NPS treatment activated antigen presenting cells, dramatically decreased immune suppressive cells both in blood and tumor microenvironment5,6. Here we found a
significant increase of tissue-resident memory T cells at early time point and a remarkable expansion of effector/
central memory T cells in later time-period. Our results indicate T cells are involved in the NPS-induced in situ
vaccination protection. Noticeably, Nuccitelli et al. reported CD8 T cells were responsible for the inhibition of
secondary tumor growth after primary tumor was ablated with NPS in the rat McA-RH7777 liver cancer model43.
Various ROS detecting agents have been adopted to measure ROS in different types of cells. Pakhomov’s group
employed 2′,7′-dichlorodihydrofluoresein (H2DCF), DHE, and Amplex Red to measure ROS products in Jurkat
(human T-lymphocytes), U937 (human monocytes), and CHO (Chinese hamster ovary) c ells31. H2DCF has
also been used by Nuccitelli’s group to detect intracellular ROS of BxPC-3 [human pancreatic cancer) cells32. In
our study, Amplex Red and DHE were utilized to examine ROS derived from 4T1 breast cancer cells. Although
different cell types were treated with various parameters of NPS in the indicated studies, a proportional increase
of ROS to the dose of NPS (the number of pulses) has been observed in all studies. It appears that the release of
ROS products is confirmed both intra- and extracellularly. One argument from Dr. Pakhomov’s report is that the
source of ROS, especially H
 2O2, can be generated from the cell free media, specifically RPMI growth medium
without serum and without phenol red, simple salt buffer, and PBS exposed to NPS. In our study, the complete
cell culture media; high glucose DMEM with 10% fetal bovine serum, non-essential amino acids and antibiotics,
was used primarily for two reasons. One being that the measurement of ROS is carried out periodically for up
to 24 h so complete media is used for the survival of control cells and to avoid nutritional shortage stress. The
second reason being that complete media most closely mimics the in vivo tumor ablation setting which has been
reported to result in vaccine-like effects5,8. Despite a concern of pro-oxidant effects of free iron in the DMEM44,
the H2O2 measurement is reported as not dependent on DMEM with or without s erum45. In addition, a continuously increasing but not a bursting pattern of H2O2 indicates a gradual generation of ROS from the electric
pulse-stressed cells (Figs. 2A, 4A-C) instead from the culturing media. Moreover, the results of MitoSox staining
which targets mitochondria specifically suggest mitochondria are one source of ROS (Fig. 3).
Surprisingly, not all antioxidants/scavengers are able to block or reduce H2O2 generation by NPS. Our results
show 4T1-luc cells pretreated with NAC significantly increase the production level of H
 2O2 by NPS (Fig. 4C).
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However, it appears NAC alone has no effect on H2O2 generation at the beginning of post-NPS treatment but
gradually increase H
 2O2 generation over time. This indicates the dose (3 mM) adopted here may cause certain
cytotoxicity, which is consistent with our viability result (Fig. 5B). The autooxidation of thiols including NAC
was proposed by several researchers46,47 however, this may explain the increase of H2O2 with NAC alone but does
not explain why NPS elevates H2O2 production. Another unexpected result is that Vitamin C induces very high
levels of H
 2O2 (Fig. 4C). In this case, NPS seems to weaken Vitamin C’s effect on ROS induction. In both cases,
the exact mechanisms of “autooxidation” of antioxidants and the impact of NPS are unknown. Nevertheless, RA,
Trolox, and sodium pyruvate at the applied concentration(s) do not show autooxidation. Their abilities to block
ROS induced by NPS are different where Trolox and sodium pyruvate significantly decrease ROS equal or close
to the level of endogenous H
 2O2 whereas RA exhibits only a partial blocking effect. It is necessary to point out
limitations regarding these assays and results. Factors, including doses of the antioxidants and media/buffers
used in the reactions have not been optimized, potentially altering the outcome.
Though ROS scavengers and antioxidants are different in terms of their working mechanisms, both groups
of substances are widely utilized to prevent cell damage or death from excessive ROS induced by drugs or
diseases39–42,48–50. Our results appear to support this concept. All five selected ROS scavengers/antioxidants
protect 4T1-luc cells from cytotoxic effect of NPS. Noticeably, when there is no NPS treatment, sodium pyruvate can stimulate breast cancer cell growth whereas other scavengers except NAC do not impact cell viability
(Fig. 5). NAC results in the reduction of cell viability in our study, which suggests the dose (3 mM) adopted here
is toxic to 4T1-luc cells. The phenomenon of growth stimulation of pyruvate has been reported by other group as
well51. However, the potency of cellular protection varies amongst those scavengers and depends on the dose of
NPS as well. RA, Vitamin C, and NAC lose protective effects at lethal doses of NPS whereas Trolox and sodium
pyruvate significantly enhance cell viability at the same doses. Although the mechanisms causing this difference
are unknown, we speculate it is associated with their ability to reduce ROS because both Trolox and sodium
pyruvate show a significant reduction of ROS in cells treated with lethal doses of NPS while others do not. The
protective effect of sodium pyruvate also leads to the issue of higher rates of tumor growth at the inoculation
site when those treated cells are used for a tumor vaccine (Fig. 7).
Unlike other groups’ studies and suggestions that ROS are associated with immunogenic cell death resulting
from chemotherapeutic drugs ( anthracyclines52) and hypericin-based photodynamic t herapy24,53, the blockade
or diminution of ROS generation from NPS does not reduce either ex vivo dendritic cell activation or in vivo
vaccine-like protective effect. On the contrary, the immunization study shows more animals are protected from
tumor challenge following vaccination with an additional ROS blocker. Though a small number of animals were
used in the studies and the differences do not reach statistical significance, similar trends in both groups of animals with ROS blockers hints to the distinct role of ROS in NPS induced immunity from that in chemotherapy.
Another puzzle is the contradiction that there is a separation between vaccine-like effects and tumor growth at
the inoculation site. The highest tumor protection rate results from NPS and sodium pyruvate treated tumor
cells, which also leads to more tumoral growth at the immunization site. As we mentioned above, increased
tumor growth at the inoculation site could be explained by an increase of viability but how additional sodium
pyruvate improves the protection remains an unknown. Nevertheless, our data imply that ROS is involved in cell
death caused by NPS but is unlikely a decisive factor for the NPS-associated vaccine effect. This supports several
groups’8,10,11 including o
 urs5,54 proposal that NPS is a novel physical ICD inducer.
We are aware of the limitations of this study due to our available resource. Only one pulse duration (60 ns) of
NPS was studied in one cancer model. The role of ROS in the cell death mechanism was not defined. Whether
the blockage of ROS could change cell death pattern and consequently enhance or reduce the immunogenicity
of NPS treated cancer cells was not elucidated either. Therefore, the ROS generation by other NPS parameters in
additional cancer types and its association with immunogenicity should be assessed further to determine if our
discoveries are general cross various tumor types or tumor-type specific.
In summary, we have demonstrated that 4T1-luc mammary cancer cells treated with NPS in vitro enhance
the tumor immunogenicity. NPS tumor ablation leads to a potent in situ vaccination protection and elicits longterm T cell immunity. The increase of both extracellular and intracellular ROS production has been observed
after tumor cells were treated with NPS. The release of ROS production correlates to the dose of NPS. Our data
supports that mitochondria are one source of ROS generation. To block ROS release from NPS treatment, the
dose and type of scavengers should be optimized to avoid toxicity from the scavenger itself and insufficient
potency. ROS scavengers partially protect cells from death induced by NPS, but even complete blockage of
ROS does not prevent cell death under lethal doses of NPS. This indicates ROS release may contribute to some
extent to the cell death resulting from NPS but is not the major contributor for that cell death. When dendritic
cells are stimulated by NPS treated cancer cells, the upregulation of their activation markers is not halted by the
blockade of ROS (in cancer cells). The immunogenicity of NPS treated cancer cells do not diminish with the
reduction or blockage of ROS. Taken together, this study suggests NPS is likely a type I ICD inducer. Currently,
we are investigating the NPS-induced cell death mechanism and its correlation with tumor immunogenicity.
The potential enhancement of immunogenicity with the blockage of ROS will be explored as well. Our hope is
the elucidation of NPS-elicited immune protection could help us further improve the therapeutic efficacy of this
novel in situ vaccination approach.

Materials and methods

Cell line. 4T1-luc murine breast cancer cells were originally provided by Dr. Gary Sahagian at Tufts University and have been maintained in high-glucose DMEM (ATCC 30–2002) (ATCC)-supplemented with 10% fetal
bovine serum, non-essential amino acids, and antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin)
(three items above from Atlanta Biologicals). 4T1-luc cells, passage numbers between 2 and 7 were thawed for
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expansion, and cells with passage numbers between 10 and 20 were used in the described ex vivo or in vivo
experiments. Cells were tested periodically to ensure no mycoplasma contamination was present.

Mice and tumor models. Female Balb/c mice (8—10 weeks of age) were purchased from Jackson Laboratory and housed in the ODU animal facility accredited by the AAALAC. 4T1-luc tumor was initiated by an
inoculation of 1 × 106 live 4T1-luc cells in the left posterior mammary fat pad in female Balb/C mice. The size of
tumor was assessed by digital calipers twice a week. Tumor volume was determined using the following formula:
V = πab2/6, where (a) is the longest diameter and (b) is the shortest diameter perpendicular to (a). All experimental protocols were approved by Old Dominion University Institutional Biosafety Committee (IBC) and
Institutional Animal Care and Use Committee (IACUC). And all experiments were performed in accordance
with relevant guidelines and regulations. At the end of the follow-up period or at specified time points described
in experimental designs, the euthanasia of mice was carried out by C
 O2 inhalation.
Reagents and antibodies. The Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit including 3% H
 2O2
for the establishment of standard curve (Cat # A-22188), Invitrogen 96-well microplates for fluorescence-based
assays (Cat # M33089), dihydroethidium (DHE) (Cat # D1168), Hoechst 33342 (Cat # H3570), and MitoSOX Red mitochondrial superoxide indicator (Cat # M36008) were purchased from Invitrogen. Trolox (Cat
# SC-200810) was obtained from Santa Cruz Biotechnology. Lipopolysaccharides (LPS) from Escherichia coli
O111:B4 (Cat # L4391), Rosmarinic acid (RA) (Cat # 536954-5G), N-acetyl cysteine (NAC) (Cat # A9165),
Vitamin C (Cat # A4403), and sodium pyruvate (Cat # P5280) were purchased from Sigma-Aldrich. WST-1
(Cat # 11644807001) for cell viability assays was obtained from Roche Applied Science. Rat anti-mouse CD3
pacific blue (Cat #100334), CD4 FITC (Cat # 100406), CD8 Percp (Cat # 100732), CD44 APC (Cat # 103012),
CD62L PE/Cy7 (Cat # 104418), IFN-γ PE (Cat # 505807), IL-17 PE/Cy7 (Cat # 506921), CD103 PE (Cat #
121406), CD86 Pacific blue (Cat # 105021), I-A/I-E FITC (Cat # 107605), CD40 APC (Cat # 124611), anti-mouse
CD16/32 (Cat # 156603), hamster anti-mouse CD11c PerCP (Cat # 117326), hamster anti-mouse CD80 PE/
Cy7 (Cat # 104734) and mouse anti-mouse H-2Kd/H-2Dd PE (Cat # 114708) were purchased from BioLegend.
In vitro NPS treatment. In vitro NPS treatment for cancer cells was described in our previous publication55.
Briefly, a custom-made nanosecond pulse generator was used to generate 60 ns (ns) electric pulses with various
pulse frequencies and applied electric fields of interest. The 60 ns pulse generator is a pulse forming line (PFL),
constructed out of five 50 Ω cables connected in parallel for a matching load of 10 Ω. The cable length was
selected to allow for a pulse to travel round-trip within 60 ns. A 1-mm cuvette loaded with 0.1 mL cell solution
was a load for the generator and to match the PFL for a square pulse. A spark gap switch with adjustable distance
was used to close the PFL and the switching medium was air for self-breakdown. Because of the stochastic nature
of the air breakdown, the pulse voltage varied within ± 10%. 4T1-luc cells, 100 μL at a concentration of 5 × 106
cells/mL in a 0.1 cm-gap cuvette were pulsed with NPS; pulse duration of 60 ns, frequency of 1 Hz, applied electric field of 5 kV (or 50 kV/cm), and pulse number of 10 to 150 dependent on experimental design. The electrical
energy per pulse, which was estimated with the pulse power (2.5 × 106 Watts) and duration (60 ns), is 0.15 Joule.
In vivo NPS treatment and the secondary tumor challenge. In vivo NPS treatment protocol was

detailed in our published paper (5). The 100 ns pulse generator is a Blumlein line, and it was constructed with
one 50 Ω cable. In this case, the matched load was 100 Ω. In addition to the tissue resistance, a 50 Ω resistor was
added in parallel to ensure a square pulse was produced. Mice with tumors (6–8 mm) were randomly grouped
according to tumor volume and treated with NPS (100 ns, 50 kV/cm, 3 Hz and 1000 pulses). Animals with tumor
free over 7 weeks were challenged orthotopically in the right posterior mammary fat pad with 0.5 × 106 live
4T1-luc tumor cells. Tumor growth was monitored twice weekly by caliper measurements.

Tissue harvesting and processing for the analysis of immune cells.

Nine days after NPS treatment,
mice were euthanized and draining lymph nodes were collected. Draining lymph nodes from tumor bearing
mice without NPS treatment were used as control. Single cell suspicions were prepared to analyze immune cells
including CD3, CD4, CD8 and tissue-resident marker CD103. To examine effect memory and central memory
T cells, animals with tumor free over 3 months after NPS treatment were euthanized. Spleens were harvested.
Spleens of tumor bearing mice were used as control. Single cell suspensions were prepared from spleens then
stained with CD3, CD4, CD8, CD44 and CD62L antibodies.
To quantify IFN-γ producing T cells, intracellular staining was carried out. Splenocytes (2 × 106/ml) 1 ml
per well were incubated with media or plate bound low endotoxin/azide free LEAF anti-CD3 Ab (0.5 µg/mL in
DPBS) in a 24-well plate. cells were incubated for 6 h and monensin added for the final 4 h.

Detection of H2O2 using the amplex red hydrogen peroxide/peroxidase assay kit. A protocol

provided by the manufacturer was modified and adopted to quantify the concentration of H2O2 released from
cells. Briefly, 4T1-luc cells were treated with various parameters of NPS as described above, following which
25,000 cells were seeded into individual wells of a 96-well plate pre-filled with 50 μL cell culture media per well.
Amplex Red reagent/HRP working solution, 50 μL, was added to each microplate well and placed in the chamber of PLUOstar Omega fluorescent microplate reader with the Atmospheric Control Unit that enables us to set
temperature at 37 °C and C
 O2 at 5%. This setting allowed for measuring the samples continuously at designated
time points and with minimal disturbance of cells. The measurement of H2O2 was done by top-reading with cell
adhered to the bottom of the plate wells without mixing. Fluorescence intensity was measured at the excitation
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of 550 nm and emission of 590 nm. Cell culture medium without cells treated with NPS (100 pulses) was used as
the background control. Serial dilutions of H
 2O2 (concentrations from 10 to 0.03125 μM) were used to establish
a standard curve. In some cases, the fluorescence intensity or relative fluorescence units (RFU) were used to
indicate the relative levels of H2O2.

Measurement of ROS by DHE. DHE (10 μM) was added into 4T1-luc cell suspensions followed by incubation at 37 °C and 5% of CO2 for 15 min. Next, the cells were treated with NPS as described above following
which 25,000 cells were then taken out of the NPS cuvette and seeded into individual wells of a 96- well plate
pre-filled with 100 μL of cell culture media (without phenol red) per well. Superoxide anion (O2¯) converts DHE
to ethidium which was monitored by the plate reader over time. The fluorescence intensity was measured as
described above with a fluorescence excitation wavelength at 520 nm and emission wavelength at 600 nm. The
difference here is that no superoxide standard curve was established, so the relative fluorescence units (RFU) was
used as the relative level of ROS.
Live cell imaging using MitoSOX Red mitochondrial superoxide indicator. Briefly, 4T1-luc cells
with or without NPS treatment were placed into a 6-well plate with 0.5 × 106 cells per well. Cells were then incubated at 37 °C, 5% C
 O2 overnight. After gentle removal of culture medium 1.0 ml of working solution containing 5 μM MitoSOX, which was made by a 1:1000 dilution from the 5 mM stock solution in DMSO into culture
media, was added into each well and the plate was incubated at 37 °C for 10 min in the dark. The incubation time
for MitoSOX loading cells was adopted according to manufacturer’s instructions. The MitoSOX working solution was then removed and replaced with nuclear staining buffer, 0.5 μg/mL Hoechst 33342 in DMEM without
phenol red. Cells were imaged immediately under a fluorescence microscope (Olympus BX51). The DAPI filter
was used to detect nuclear staining and the TRITC filter was used to detect oxidized MitoSOX Red in the cells.
Cell viability assay.

WST-1 cell viability assay was described previously55. Briefly, 10 µL (5 × 106/mL) of
cell suspension after exposure to NPS with or without ROS blockers was placed into a clear-flat-bottom 96-well
plate filled with 90 µL complete medium per well. All ROS blockers including Trolox (1 mM), RA (100 μM),
Vitamin C (0.5 mM), NAC (3 mM) and Sodium pyruvate (10 mM), and with their corresponding concentrations previously screened for their ability to block ROS generation were examined by cell viability assays. Cells
were incubated at 37 °C and 5% C
 O2. Following an 18-h incubation 10 μL of WST-1 reagent was added to each
well. Cells were incubated with WST-1 for 2 h and then measured by Multiskan MCC/340 microplate reader
(Fisher Scientific, Hampton, NH) with a test wavelength of 450 nm and a reference wavelength of 630 nm. Cell
viability (%) was calculated using the formula: Treated sample (OD450-OD630)/control (OD450-OD630) × 100.
4T1-luc cells without NPS exposure but otherwise treated the same way as those exposed to NPS were used as
the control.

Generation and activation of bone marrow‑derived DCs (BMDCs).

BMDCs were prepared from
harvested bone marrow cells by 8 days of culture and differentiation in the presence of 20 ng/ml GM-CSF
(R&D). BMDCs (2 × 105) were then incubated with 4T1-luc cells (2 × 105) treated with a lethal dose of NPS (100
pulses, 60 ns, 50 kV/cm and 1 Hz) alone or with the addition of Trolox (1 mM) in a 24-well plate at 37 °C, 5%
of C
 O2 for 2 days. BMDCs in the presence of either media alone or LPS (5 μg/mL), but without 4T1-luc cells,
were used as negative and positive controls, respectively. Cells were harvested to analyze cell surface activation
markers (MHC-I/II, CD40 and CD80) by flow cytometry.

Vaccination and tumor challenge. Mice were shaved and subcutaneously (SC) inoculated with 3 × 106

NPS treated 4T1-luc cells with or without a ROS blocker in 100 μL sterile saline. Control animals were inoculated SC with the same quantity of cells lysed with 3 freezing/thawing cycles. There were 4 groups: control (Ctrl),
NPS treated cells (NPS), NPS treated cells with preincubation with Trolox 1 mM (NPS + Trolox) or sodium
pyruvate 10 mM (NPS + SP). All 20 mice (n = 5 per group) were challenged with 0.5 × 106 4T1-luc live cells in 50
μL sterile saline in the left posterior mammary fat pad 10 days later. Tumor growth was monitored twice weekly
by caliper measurements. Animals with complete tumor rejection were followed for at least 4 months, and those
with tumor growth were euthanized when the volume of tumor reached 1.5 cm3 unless euthanasia was required
earlier due to other criteria described for experimental endpoints in the approved IACUC protocol.

Flow cytometry analysis. 2 × 105 BMDCs were incubated with an antibody cocktail (anti-MHC-I/II,
CD40 and CD80, each at 1 μg per million cells) in 100 μL FACS buffer (2% FBS DPBS) at room temperature for
30 min. Cells were then washed with 2 mL FACS buffer twice and resuspended in 0.5 mL FACS buffer for flow
cytometric analysis by MACSQuant Analyzer 10 (Miltenyi Biotec). Cells stained with isotype antibodies were
used as negative controls. All stained cells were run through a flow cytometer. Live cells were gated in a forward
scatter (FSC) versus side scatter (SSC) plot then analyzed for cell surface biomarkers.
For intracellular staining, 2 × 106 splenocytes were prepared by pre-incubation with purified anti-CD16/32
(Fc block), followed by surface labeling of cells with anti-CD3 pacific blue, anti-CD4 FITC and anti-CD8 PerCP
followed by intracellular staining using mAbs anti-IL-17A PE-Cy7 and anti-IFN-γ PE after fixation and permeabilization with fixation and permeabilization buffer. Samples were analyzed on a flow cytometer (FACSAria,
BD Biosciences).
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Statistical analysis. Values were presented as the mean ± standard deviation (SD) or standard error (SE).
Student’s t test was utilized to compare quantitative data including tissue-resident memory, effector and central
memory T cells between two groups. One Way ANOVA (3 or more groups) was utilized to analyze the quantitative data including cell viability and the level of ROS (H2O2 concentration or RFU). To compare the dynamic
change of ROS among different treatment groups, the accumulated ROS or area under curve was calculated and
analyzed. If One Way ANOVA showed statistical significance, then Pairwise Multiple Comparison Procedures
(Holm-Sidak method) would be done to compare various pairs of groups. Chi-square was employed to analyze
the vaccine effect or the rate of protection. If Chi-square for multiple groups showed statistical significance, then
Pearson Correction and Chi-square between two groups would be done to compare two groups. Animal survival
will be analyzed with Kaplan–Meier Survival LogRank analysis. Statistical significance is assumed at p < 0.05. All
statistical analysis was completed using SigmaPlot 12.0 (Systat Software, Inc., San Jose, CA).
Ethical approval. All animal experiments in this study were reported in accordance with ARRIVE guidelines. All 10 Essential requirements were described in the sections of Material & Methods and Results.
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